Factors | Univariate analysis | Multivariate analysis | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Progression-free survival | Overall survival | Progression-free survival | Overall survival | |||||||||
P value | HR | 95 % CI | P value | HR | 95 % CI | P value | HR | 95 % CI | P value | HR | 95 % CI | |
Time from ADT to CRPC (<10 vs ≥ 10 months) | 0.0306 | 2.191 | 1.057–4.542 | 0.0002 | 4.566 | 1.913–10.898 | 0.816 | 1.104 | 0.49–2.489 | 0.0336 | 2.656 | 1.061–6.648 |
ECOG (2–3 vs 0–1) | 0.273 | 1.51 | 0.718–3.176 | 0.0034 | 3.392 | 1.426–8.071 | N.A. | N.A. | N.A. | 0.0001 | 4.907 | 1.648–14.612 |
Age (<75 vs ≥75) | 0.2687 | 0.664 | 0.319–1.381 | 0.8875 | 1.068 | 0.43–2.653 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. |
Gleason score ( ≥8 vs <8) | 0.9539 | 1.023 | 0.471–2.225 | 0.9549 | 0.973 | 0.376–2.515 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. |
Visceral met (yes vs no) | 0.0088 | 4.7 | 1.313–16.82 | 0.0007 | 6.907 | 1.881–25.357 | 0.0126 | 5.891 | 1.43–24.267 | 0.0015 | 4.8 | 1.026–22.465 |
Symptomatic (yes vs no) | 0.6554 | 1.183 | 0.565–2.476 | 0.1193 | 1.966 | 0.826–4.682 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. |
PSA doubling time (<2 months vs ≥2 months) | 0.1667 | 1.651 | 0.804–3.393 | 0.4794 | 1.573 | 0.568–3.319 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. |
Baseline PSA ( ≥200 vs <200 ug/l ) | 0.0014 | 3.26 | 1.513–7.021 | 0.0365 | 2.558 | 1.028–6.364 | 0.0686 | 2.15 | 0.933–4.954 | 0.6339 | 1.313 | 0.428–4.038 |
Baseline ALP ( ≥120 vs <120 IU/l) | 0.1464 | 1.69 | 0.825–3.466 | 0.0535 | 2.459 | 0.987–6.13 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. |
Baseline Hb (<12 vs ≥12 g/dl) | 0.1618 | 1.676 | 0.805–3.488 | 0.023 | 2.712 | 1.109–6.631 | N.A. | N.A. | N.A. | 0.0409 | 2.696 | 0.912–7.7971 |
PSA response (yes vs no) | <0.0001 | 0.135 | 0.061–0.299 | 0.0001 | 0.176 | 0.067–0.459 | <0.0001 | 0.186 | 0.079–0.439 | 0.0001 | 0.104 | 0.025–0.387 |
PSA flare (yes vs no) | 0.0623 | 0.471 | 0.209–1.06 | 0.0652 | 0.373 | 0.125–1.111 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. |
Continuation of AA beyond progression (yes vs no) | N.A. | N.A. | N.A. | 0.9863 | 0.992 | 0.382–2.574 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. |
Post-AA treatment (yes vs no) | N.A. | N.A. | N.A. | 0.3604 | 0.51 | 0.117–2.219 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. |